Apr 2014-Global Lifesciences Business in India

Top Highlights for April 2014: (Please click on read more to see details)

Indian pharma industry accounts for 25% of global pharma by volume.
Sun Pharma to acquire Ranbaxy in a US$ 4 billion transaction.
Glenmark receives US$ 5 million as milestone fee payment from Sanofi.
Dutch Royal DSM invested over $10 million to establish new human nutrition plant in India. Read more
US Ashland Inc has invested $ 10 million in Indian pharma sector. Read more
India’s EID Parry acquired Chile based Alimtec SA from Bayer nutraceutical arm for $2.63 million.Read more
Top Japanese pharma companies scouting for business opportunities in Indian drug market. Read more
Japan’s Yoshindo and India’s Lupin ink strategic joint venture. Read more
US, India to begin collaborative research for finding affordable blood pressure (BP) measurement technologies. Read more
Argentina and India to commence joint research in biotechnology, medical sciences and healthcare.Read more
Sabinsa Corporation licences Two Patents From Indian Institute Of Integrative Medicine And The Indian Council Of Medical Research. Read more

For more such news and updates on Global Life Science Business in India please join this group at LinkedIn

Featured Opportunities and Aagami Updates: (Please click on link to view details)

1. Product Licensing opportunities:

Elores– to combat antimicrobial resistance – Looking for partner to Launch in US. Already launched in India and partnership completed for South Africa and South Korea.
Partnership sought for low cost, stable, safe, malaria cure which overcomes drug resistance and is ready for human clinical trials.
Co-Development/Partnership opportunity in Oncology and STEMI with an Innate Immune Drug Development Company based in Ireland.
Co-development Opportunity with a US company in innovative Breast cancer vaccine and Prostate cancer vaccine.

2. Technology Licensing available for:

Biological alternative to PEGylation Technology to extend plasma half-life (10-100 fold), improve in vivo activity, allow less frequent and lower dosing combined with better patient tolerability.
Innovative Chemotherapy - "Targeted Transferrin Transport Technology”.
The very first NANOTECHNOLOGY based diagnostic platform - future of science in MI.
Opportunity to Partner on new linker technology which combines Paclitaxel/ Doxorubicin/ Docetaxel with Albumin and make better generic of these drugs which can easily take the 5052b pathway and will be patent protected.
Transdermal drug delivery technology: TPM® – “Targeted Penetration Matrix” – applicable as a delivery system as an active across multiple products & markets.

3. India Amazing Facts and Figures: A report presenting interesting facts on India's LifeScience Industry and the country's economy in general.